期刊文献+

内置式佐剂LTB对空肠弯曲菌重组蛋白疫苗免疫增强作用的研究 被引量:3

RESEARCH ON THE IMMUNOLOGIC ENHANCEMENT OF RECOMBINANT PROTEIN VACCINE FROM PEB1-LTB CONSTRUCTION MODEL
下载PDF
导出
摘要 目的构建空肠弯曲菌(CJ)外膜蛋白(PEB1)及大肠埃希菌LTB融合疫苗并研究其免疫原性。方法应用重组PCR技术将PEB1和LTB序列连接,构建PEB1-LTB融合基因,将其克隆入原核表达载体pET-28a,转化入大肠埃希菌BL21,SDS-PAGE电泳表达,Western印迹检测表达蛋白的抗原性。肌注方式免疫小鼠,末次免疫2周后,测定小鼠血清中IgG、IgA及黏膜冲洗液中sIgA抗体水平。结果 PCR扩增分别获得约787、372bp产物,二者融合后获得一约1180bp目的基因;该重组蛋白可具有良好的免疫原性,肌注小鼠后其血清IgG、IgA及黏膜冲洗液中sIgA含量均显著增高(P<0.01)。结论构建PEB1-LTB融合蛋白可有效增强小鼠免疫应答水平。 Objective To construct a fusion vaccine of C jejuni PEB1 protein and Escherichia coli heat-labile enterotoxin B(LTB),i.e.PEB1-LTB,and to study the immunogenicity of the fusion vaccine.Methods The PEB1 and LTB were amplified by recombinant PCR to construct a fusion gene.The fusion gene was subcloned into a procaryon expression vector PET-28a and was then transformed into E.coli BL21.SDS-PAGE electrophoretic expressions were got.The antigenicity of the recombinant fusion protein was analyzed by Western blotting.Two weeks after the final immunization of mice through intramuscular injections,the antibodies and cytokines were detected,including the specific IgG and IgA antibodies in serum,sIgA in mucosa douche.Results The PCR fragments of PEB1,LTB and PEB-LTB were about 787,372bp and 1180bp respectively.The recombinant protein had good immunogenicity.The levels of IgG,IgA and sIgA antibodies were all higher than those in other groups(P0.01).Conclusion The construction of the fusion protein of PEB1-LTB in E.coli cells can effectively enhance the immune response of mice.
出处 《山东医学高等专科学校学报》 2012年第1期12-14,共3页 Journal of Shandong Medical College
基金 临沂市科技发展计划项目(No.201013066)
关键词 重组PCR 空肠弯曲菌 大肠埃希菌 不耐热肠毒素 融合基因 Recombinant PCR Campylobacter jejuni Escherichia coli Heat-labile enterotoxin Fusion gene
  • 相关文献

参考文献1

共引文献6

同被引文献31

  • 1郭桐生,邹全明,郭刚,解庆华,刘开云,曾韦锟,高志刚.重组幽门螺杆菌疫苗口服免疫BALB/c小鼠的研究[J].中华微生物学和免疫学杂志,2005,25(3):239-242. 被引量:3
  • 2杨巨飞,邱利焱,金一,沈圆圆.口服胸腺肽肠溶微球的制备及其体内外评价[J].中国药学杂志,2006,41(21):1638-1641. 被引量:5
  • 3Snetling W J, Matsuda M, Moore J E et al. Campylobacter jejani[J]. Lett Appl Microbiol, 2005, 41(4): 297-302.
  • 4Chao HC, Chert CC, Chvn SY, et al. Bacterial enteric infections in childn: etiology, clinical manifestations and antimicrobial therapy[J]. Expert Rev Anti Infect Ther, 2006, 4(4): 629-638.
  • 5Pizza M, Giuliani MM, Fortran MR, et al. Mueosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants[J]. Vaccine, 2001, 19(17-19): 2534-2541.
  • 6Ahmad G,Zhang W, Torben W, et al. Prime-boost and recombinant protein vaccination s-ategies using Sin-p80 protects againstSchistosoma mansoni infection in the mouse model to levels . previously attainable only by the irradiated eercarial vaccine[J]. Parasitol Res, 2009, i05(6): 1767-1777.
  • 7Cui Z. DNA vaccine[J]. Adv Genet, 2005, 54: 257-289.
  • 8Cassataro J, Velikovsky CA, Bruno L, et aL Improved immunogenieity of a vaccination regimen combining a DNA vaccine encoding Brucella melitettsis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting[J]. Clin Vaccine Immunol, 2007, 14(7): 869-874.
  • 9Wang S, Kennedy JS, West K, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-proteinboost HIV-1 vaccine in healthy human volunteers[J]. Vaccine, 2008, 26(8): 1098-1110.
  • 10Rafati S, Ghaemimanesh F, Zahedifard E Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against leishmania major infection using signal peptidase type I in BALB/c mice[J]. Vaccine, 2006, 24(16): 3290-3297.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部